Why Moderna (MRNA) stock is trading lower today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur
What's Your Reaction?
